Skip to main content
logo
Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.9216
+0.0362 (4.09%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Akebia Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
219.06236.2160.18194.62292.48211.65
Revenue Growth
7.52%47.46%-17.70%-33.46%38.19%-28.17%
Gross Profit
178.37195.84134.03154.86269.99130.16
Operating Income
-5.8826-46.21-44.5-34.64-227.88
Net Income
-29.67-5.35-69.41-51.93-94.23-282.02
Earnings Per Share
-0.11-0.02-0.33-0.28-0.52-1.70
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
155.55184.8451.8742.9390.47149.8
Total Debt
199.19198.78188.73144.28157.27189.13
Net Cash (Debt)
-43.64-13.94-136.86-101.35-66.8-39.33
Net Cash Growth
------
Net Cash Per Share
-0.16-0.05-0.65-0.54-0.37-0.24

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
41.5567.99-40.66-23.38-73.15-252.97
Capital Expenditures
-1.29-0.29-0.03--0.11-0.06
Free Cash Flow
40.2667.7-40.69-23.38-73.27-253.02
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
81.43%82.92%83.68%79.57%92.31%61.50%
Operating Margin
-2.68%11.01%-28.85%-22.86%-11.84%-107.67%
Pretax Margin
-12.71%-1.58%-43.33%-26.68%-32.22%-133.25%
Profit Margin
-13.54%-2.26%-43.33%-26.68%-32.22%-133.25%
FCF Margin
18.38%28.66%-25.40%-12.02%-25.05%-119.55%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-82.5618.7218.7218.7218.72
P/FCF Ratio
6.156.31----
PS Ratio
1.131.812.591.200.361.87